Peringkat dalam Saham
#40870
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Harga Saham
$0.02765
Terakhir disinkronkan: 2024-12-23
Kapitalisasi Pasar
$69.04K
Perubahan (1 tahun)
0.00%
Perdagangan Histogen Inc. (HSTO)
Harga HSTO dengan kapitalisasi pasar B
Kapitalisasi pasar dari Histogen Inc.(HSTO)
Kapitalisasi Pasar: $69.04K
Per August 2026, Histogen Inc. memiliki kapitalisasi pasar sebesar $69.04K. Ini menjadikan Histogen Inc. sebagai perusahaan 40870th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Histogen Inc. dari 2013 hingga 2026
HSTO dibandingkan dengan 5 teratas stocks paling populer
| Harga HSTO |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.448T
|
+7,890,461,518.54%
|
|
|
|
|
$4.457T
|
+6,454,884,178.61%
|
|
|
|
|
$4.187T
|
+6,064,079,670.10%
|
|
|
|
|
$3.697T
|
+5,354,002,319.35%
|
|
|
|
|
$2.887T
|
+4,181,340,006.50%
|
